Guwahati Mail

Oral Mucositis Market Size is anticipated to grow by 2034, estimates DelveInsight

 Breaking News
  • No posts were found

Oral Mucositis Market Size is anticipated to grow by 2034, estimates DelveInsight

June 11
19:05 2024
Oral Mucositis Market Size is anticipated to grow by 2034, estimates DelveInsight

DelveInsight’s “Oral mucositis Market Insight, Epidemiology and Market Forecast – 2034” report delivers an in-depth analysis of Oral mucositis epidemiology, market, and clinical development in Oral mucositis. In addition to this, the report provides historical and forecasted epidemiology and market data as well as a detailed analysis of the Oral mucositis market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.


Explore the intricate details of the Oral Mucositis Market: Uncover drug uptake, treatment dynamics, and epidemiological trends with our comprehensive Oral Mucositis Market Forecast. Click here to stay ahead in healthcare innovation @ Oral Mucositis Market Size


Key Takeaways from the Oral Mucositis Market Report

  • June 2024:- EpicentRx Inc.-A Randomized Placebo-Controlled Trial of Two Schedules of RRx-001 for the Attenuation of Severe Oral Mucositis in Patients Receiving Concomitant Chemoradiation for the Treatment of Locally Advanced Squamous Cell Carcinoma of the Oral Cavity or Oropharynx.
  • June 2024:- Klaus Gottlob Müller- The primary objective of this clinical trial is to ievaluate the effect of semaglutide (GLP-1 receptor agonist) in reducing intensity of gastrointestinal (GI) mucositis in patients undergoing high-dosage chemotherapy followed by autologous (auto) haematopoietic stem cell transplantation (HSCT). The secondary objective is to evaluate the effect and safety of semaglutide in reducing gut barrier injury and systemic inflammation in patients undergoing auto-HSCT.
  • June 2024;- Zhejiang Echon Biopharm Limited- A Multicenter, Randomized, Double-blind, Placebo-controlled Phase IIa Clinical Trial to Evaluate the Efficacy and Safety of Oral Local Use of GB001 Recombinant Peptide Spray for the Treatment of Mild Recurrent Aphthous Ulcer.
  • According to Bell and Kasi (2023), patients who receive high doses of chemotherapy or undergo bone marrow transplantation have a 76% risk of mucositis. The frequency of mucositis is higher in patients with poor nutritional status and inadequate oral care. Younger age patients may have a higher incidence of Oral Mucositis.
  • According to Pacheco et al. (2021), in patients undergoing head and neck cancer treatment, the overall oral mucositis incidence was 89.4%. The global incidence for mild, moderate, and severe degrees were 16.8%, 34.5%, and 26.4%, respectively.
  • According to Claudio et al. (2020), about 40% of the patients treated with chemotherapy develop mucositis; this percentage rises to about 90% for head and neck cancer patients (HNC) treated with both chemo- and radiotherapy.
  • The leading Oral Mucositis Companies such as Access Pharmaceuticals, Chemo Mouthpiece, Aurora BioScience, Camurus, Innovation Pharmaceuticals, Enzychem Lifesciences Corporation, BrainCool, NeoMedLight, Monopar Therapeutics, MuReva (Lumitex), EpicentRx, Prothex Pharma, Soligenix and others.
  • Promising Oral Mucositis Therapies such as KAPIVANCE (palifermin), BupiZenge, Avasopasem manganese (GC4419), and others.


Delve deep into the Oral Mucositis Market Landscape: Analyze drug adoption, treatment paradigms, and epidemiological shifts in our detailed Oral Mucositis Market Forecast. Click here to shape the future @ Oral Mucositis Epidemiology Insights


Oral Mucositis Overview

Oral mucositis is a condition characterized by inflammation and ulceration of the mucous membranes lining the mouth and throat. It is a common side effect of cancer treatments such as chemotherapy and radiation therapy, particularly when these therapies target rapidly dividing cells, which includes the cells of the oral mucosa.


Oral Mucositis Epidemiology Insights

  • Oral Mucositis Grade-Specific Incident Cases
  • Total Oral Mucositis Incident Cases
  • Total Oral Mucositis Treated Cases


Navigate the complexities of the Oral Mucositis Market: Gain insights into drug trends, treatment scenarios, and epidemiological data through our insightful Oral Mucositis Market Forecast. Click here to get more insights @ Oral Mucositis Treatment Market


Oral Mucositis Market Insights

Management of oral mucositis is divided into the following sections: nutritional support, pain control, oral decontamination, palliation of dry mouth and therapeutic interventions for oral mucositis. Topical agents, analgesics, mucosal protectants, etc. are used. The other treatment options may include interventions to reduce the mucosal toxicity of chemotherapy drugs, mouthwashes, immunomodulatory agents, topical anesthetics, mucosal barriers and coating agents, cytoprotectants.


Oral Mucositis Market Growth Factor

Oral Mucositis Market Growth is expected to be mainly driven by increasing incidence of cancer cases, expected approval and readily penetration of emerging therapies, and increase in Research and Development activities. Thus, the dynamics of Oral Mucositis market is anticipated to experience a positive shift during the forecasted period (2024–2034). Reduction in the proliferative capacity of oral epithelial cells is thought to play a role in the pathogenesis of mucositis. Recent evidence shows that IV recombinant human keratinocyte growth factor-1 (Palifermin) significantly reduced incidence of WHO grade 3 and 4 oral mucositis in patients with hematologic malignancies (e.g. lymphoma and multiple myeloma) receiving high-dose chemotherapy and total body irradiation before autologous hematopoetic cell transplantation.


Unlock insights into the Oral Mucositis Market: discover drug uptake patterns, treatment landscapes, and epidemiological insights with our exclusive Oral Mucositis Market Forecast. Click here @ Oral Mucositis Market Drivers and Barriers


Oral Mucositis Drugs Uptake

  • KEPIVANCE (palifermin), developed by Amgen/ Swedish Orphan Biovitrum, is a truncated human keratinocyte growth factor (KGF) produced by recombinant DNA technology in E coli. In December 2004, the US FDA approved Kepivance (palifermin), making it the first therapy to decrease the incidence and duration of severe oral mucositis (mouth sores) in patients with hematologic (blood) cancers undergoing high-dose chemotherapy, with or without radiation, followed by a bone marrow transplant.
  • EPISIL, developed by Camurus, is a lipid-based fluid that transforms into a thin bioadhesive film when in contact with the buccal membrane, alleviating pain by protecting mucous membranes. In September 2011, Camurus announced that that it has received 510(k) clearance from the US FDA to market Episil in the US for management and relief of oral pain.
  • MuGard is a mucoadhesive oral wound rinse and is a viscous hydrogel polymer solution which is dispensed in a ready-to-use form. MuGard works by adhering (sticking) to the mucosal surface of the mouth. In December 2006, MuGard received marketing allowance in the US from the FDA under a 510(k) procedure for radiation and chemotherapy side effects.


Oral Mucositis Therapies and Companies

  • Kepivance (Palifermin): Amgen/ Swedish Orphan Biovitrum
  • MuGard: Access Pharmaceuticals
  • Chemo Mouthpiece: Chemo Mouthpiece/ Aurora BioScience
  • Episil: Camurus
  • Brilacidin: Innovation Pharmaceuticals
  • EC-18: Enzychem Lifesciences Corporation
  • Cooral System: BrainCool
  • CareMin650: NeoMedLight
  • Validive (Clonidine Lauriad): Monopar Therapeutics
  • MuReva Phototherapy System: MuReva (Lumitex)
  • RRx-001: EpicentRx/Prothex Pharma
  • SGX942: Soligenix


Oral Mucositis Marketed Drugs


  • KEPIVANCE (palifermin): Swedish Orphan Biovitrum

KEPIVANCE is a recombinant human keratinocyte growth factor that works at the cellular level to help protect patients with hematologic malignancies undergoing high-dose chemotherapy and/or radiation followed by bone marrow transplant from severe oral mucositis. The drug received FDA approval in December 2004 to reduce the incidence and duration of severe oral mucositis in these patients by protecting the epithelial cells that line the mouth and throat from the damage caused by chemotherapy and radiation and by stimulating the growth and development of new epithelial cells to build up the mucosal barrier.


Oral Mucositis Emerging Drugs


  • Avasopasem manganese (GC4419): Galera Therapeutics

Avasopasem manganese is an investigational, highly selective small molecule superoxide dismutase (SOD) mimetic that is being developed for the reduction of radiation-induced severe oral mucositis. It is designed to rapidly and selectively convert superoxide to hydrogen peroxide and oxygen, protecting normal tissue from damage associated with radiation therapy. Avasopasem received Breakthrough Therapy and Fast Track Designations from the US FDA for the reduction of the incidence and severity of radiation-induced oral mucositis in head and neck cancer. Currently, the drug has completed a Phase III (NCT03689712) trial (ROMAN) to evaluate the reduction in oral mucositis with GC4419 (avasopasem manganese) if administered prior to intensity-modulated radiation therapy (IMRT) in patients receiving chemoradiotherapy for locally-advanced, non-metastatic head and neck cancer.


  • RRx-001: EpicentRx

RRx-00, is a direct NLRP3 inhibitor and Nrf2 up regulator that has anti-inflammatory and antioxidant properties. It inhibits glucose 6-phosphate dehydrogenase (G6PD) in human tumor cells, binds hemoglobin, and drives RBC-mediated redox reactions. It triggers apoptosis and exhibits anticancer activity. The company has completed a Phase II (NCT03515538) trial (PREVLAR) to evaluate the safety and efficacy of RRx-001 in the attenuation of oral mucositis in patients receiving chemoradiation for the treatment of oral cancers and is currently evaluating the drug in another ongoing Phase II (KEVLARx) trial for reducing oral mucositis in patients receiving chemotherapy and radiation for head and neck cancer.


Oral mucositis Market Outlook

Oral mucositis is a common and feared adverse effect in patients with cancer who undergo anticancer treatment. The management of mucositis can be quite vexing for both the patient and the oncologist. Uncomplicated mucositis is generally self-limiting, and symptom management and supportive care may be all that is needed. Normal saline or sodium bicarbonate solutions can provide relief of mild to moderate mucositis pain.10 Such salt-and-soda mouthwashes are also safe, inexpensive, and effective in treating Chemotherapy-induced mucositis. Clinically, radiation-induced mucositis can be also managed similarly to chemotherapy-induced mucositis. Mouthwashes that contain the tricyclic antidepressant doxepin have also been trialed in radiation-induced mucositis. In patients who receive mTOR inhibitor therapy, dexamethasone mouthwashes are effective at reducing the incidence and severity of mucositis with minimal adverse effects.


Scope of the Oral Mucositis Market Report

  • Coverage- 7MM
  • Oral Mucositis Companies- Access Pharmaceuticals, Chemo Mouthpiece, Aurora BioScience, Camurus, Innovation Pharmaceuticals, Enzychem Lifesciences Corporation, BrainCool, NeoMedLight, Monopar Therapeutics, MuReva (Lumitex), EpicentRx, Prothex Pharma, Soligenix and others.
  • Oral Mucositis Therapies- KAPIVANCE (palifermin), BupiZenge, Avasopasem manganese (GC4419), and others.
  • Oral Mucositis Market Dynamics: Oral Mucositis Market drivers and Oral Mucositis Market Barriers
  • Oral Mucositis Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Oral Mucositis Unmet Needs, KOL’s views, Analyst’s views, Oral Mucositis Market Access and Reimbursement


Gain a strategic edge in the Oral Mucositis Market: explore comprehensive drug insights, treatment updates, and epidemiological forecasts in our in-depth Oral Mucositis Market Forecast. Click here to lead in advancements @ Oral Mucositis Clinical Trials Assessment


Table of Content

1 Key Insights

2 Report Introduction

3 Executive Summary

4 Key Events

5 Epidemiology and Market Forecast Methodology

6 Oral Mucositis Market Overview at a Glance

7 Disease Background and Overview

8 Treatment and Management

9 Epidemiology and Patient Population

10 Patient Journey

11 Marketed Therapies

12 Emerging Therapies

13 Oral Mucositis: 7 Major Market Analysis

14 Unmet Needs

15 SWOT Analysis

16 KOL Views

17 Market Access and Reimbursement

18 Appendix

19 DelveInsight Capabilities

20 Disclaimer


About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States